Abstract | Urolithiasis affects approximately 10% of individuals in Western societies by the seventh decade of life. The most common form, idiopathic calcium oxalate urolithiasis, results from the interaction of multiple genes and their interplay with dietary and environmental factors. To date, considerable progress has been made in identifying the metabolic risk factors that predispose to this complex trait, among which hypercalciuria predominates. The specific genetic and epigenetic factors involved in urolithiasis have remained less clear, partly owing to the candidate gene and linkage methods that have been available until now, being inherently low in their power of resolution and in assessing modest effects in complex traits. However, together with investigations of rare, Mendelian forms of urolithiasis associated with various metabolic risk factors, these methods have afforded insights into biological pathways that seem to underlie the development of stones in the urinary tract. Monogenic diseases account for a greater proportion of stone formers in children and adolescents than in adults. Early diagnosis of monogenic forms of urolithiasis is of importance owing to associated renal injury and other potentially treatable disease manifestations, but diagnosis is often delayed because of a lack of familiarity with these rare disorders. In this Review, we will discuss advances in the understanding of the genetics underlying polygenic and monogenic forms of urolithiasis.
Introduction
Familial clustering of idiopathic calcium oxalate uro lithiasis was observed as early as the 19 th century, which indicated a genetic basis. 1, 2 For decades, familybased linkage and candidate gene studies have formed the foundation of our understanding of genetic suscep tibility factors for urolithiasis, highlighting a role for disturbances in calcium homeostasis. The first genome wide association study in idiopathic calcium oxalate urolithiasis was published in 2009, and identified a member of the claudin gene family (CLDN14) as a risk locus. 3 Members of the same gene family (CLDN16 and CLDN19) have been implicated in monogenic forms of hypercalciuria, 4, 5 which illustrates how complex and simple traits with a common phenotype can interface at the genetic level. For singlegene Mendelian dis orders associated with urolithiasis, discovery of the causative genes and recognition of their variation has made molecular diagnostics and pharmacogenomics pos sible. At the same time, these discoveries have provided a wealth of suitable candidates to study as quantitative trait loci in the common complex form of the disease. In this Review, we will summarize the genetic advances in common (polygenic) and rare (monogenic) forms of urolithiasis.
Idiopathic calcium oxalate urolithiasis
Idiopathic calcium oxalate urolithiasis is a common disorder, affecting approximately 10% of indivi duals in developed countries by the seventh decade of life. [6] [7] [8] This condition is a significant cause of morbidity as recurrence rates are 50% at 5-10 years and surgical intervention is often required. 6, [9] [10] [11] [12] [13] Some studies have also suggested potential associations with diabetes mellitus, hypertension and loss of renal function.
oxalate stoneforming patients than in relatives of control individuals. 19 Coe et al. reported an increased incidence of both hypercalciuria and urolithiasis (43%) in first degree relatives of nine probands with hypercalciuria and recurrent calcium oxalate urolithiasis. 20 In a large cohort of 37,999 male health professionals, the adjusted relative risk of incident kidney stone formation was 2.57 in men with a positive family history of hypercalciuric uro lithiasis (versus those without a family history of stones). 21 From these and other studies, the likelihood of kidney stone formers having firstdegree relatives or more distantly related family members who are also affected has been estimated at 15-65%. 22, 23 Studies of kidney stoneforming twins have demon strated a higher concordance for kidney stones in monozygotic than in dizygotic twins (32% versus 17%, respectively, in one study 24 ), with estimates of heritability of 52-56%. [24] [25] [26] Linkage and candidate gene studies Because the majority of kidney stones are calcium containing, 27 and because hypercalciuria is the most commonly identified metabolic risk factor for uro lithiasis, the search for susceptibility loci in patients with idiopathic calcium oxalate urolithiasis has logi cally focused on genes involved in calcium metab olism. Selective breeding of Sprague-Dawley rats with the highest levels of urinary calcium for more than 30 genera tions has yielded animals with a pheno type resembling abnormalities of calcium handling observed in subsets of human patients with idiopathic hypercalciuria. 28 These abnormalities include intestinal calcium hyperabsorption, increased bone resorption and impaired renal tubular calcium reabsorption. 29 Detailed studies in these rats have demonstrated elevated levels of the vitamin D receptor in intestine, bone and kidney, which has also been reported in peripheral blood mono cytes of some patients with idiopathic hypercalciuria. 30 In this rat model of genetic hypercalciuria, upregulation of the vitamin D receptor was shown to be mediated by Snail, a gene coding for a zinc finger transcription factor. 31 Homologs of the quantitative trait loci associ ated with hypercalciuria in these animals have served as candidate genes in human idiopathic hypercalciuria. The candidate loci in idiopathic hypercalciuria and calciumcontaining urolithiasis are listed in Table 1 . Candidate genes associated with monogenic causes of hyper calciuria are summarized later in this Review.
Key points
■ Calcium oxalate urolithiasis most often presents as a complex trait, which arises from the interaction of multiple genes and their interplay with dietary and environmental factors ■ The search for genetic factors underlying the most common idiopathic form of urolithiasis has yielded a number of promising candidate genes ■ Urolithiasis is also a manifestation of rare, single-gene disorders, many of which present in childhood or adolescence ■ Early diagnosis of monogenic causes of urolithiasis is necessary to prevent renal injury or other disease manifestations; however, diagnosis is often delayed owing to unfamiliarity with these rare, single-gene disorders showed that the vitamin D receptor content in peripheral blood monocytes was twofold greater in male calcium oxalate stone formers with idiopathic hypercalciuria than in controls (49 ± 21 fmol/mg versus 20 ± 15 fmol/mg, respectively; P <0.008).
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The calcium-sensing receptor A study from Italy that included 125 women recruited from an outpatient osteoporosis clinic indicated a link between hypercalciuria and a rare functional single nucleotide polymorphism (R990G) of the calcium sensing receptor gene (causing a gainoffunction of the receptor). 35 However, nonparametric linkage and quantitative trait analyses in 64 French Canadian sib ships of calcium oxalate and phosphate kidney stone formers with varying degrees of calciuria did not reveal an associa tion with microsatellite markers in the region of the calciumsensing receptor gene. 36 
Soluble adenylyl cyclase
Linkage to chromosome 1q23.3-q24, a region contain ing a putative gene homologous to the rat gene coding for soluble adenylyl cyclase, was demonstrated in three kindreds with absorptive hypercalciuria. 37 Four sequence variants (coding and noncoding) in this putative gene seemed to increase the risk of absorptive hypercalciuria and low bone mineral density. 38 Epithelial calcium channel/TRPV5 Over a decade ago, a novel epithelial channel with a capacity for calcium transport was identified in the distal nephron and proximal small intestine and referred to as the epithelial calcium channel. 39 In the kidney, this calcium channel was shown to co localize to the apical membrane of distal renal cells with vitamin Ddependent calbindinD 28K , and to possess highly selective calcium transport properties, pointing to a role as a transcellular calcium 'gatekeeper' . 39 Molecular screening of this epi thelial calcium channel in nine pedigrees with idiopathic hypercalciuria did not reveal any pathogenic sequence variants. 40 However, this epithelial calcium channel is now known as the apical transient receptor potential cation channel subfamily V member 5 (TRPV5), which acts in close concert with Klotho to modulate calcium reabsorption in the distal renal tubule, a function regu lated by vitamin D, parathyroid hormone and potentially other molecules (such as WNK4).
41 TRPV5knockout mice show substantial disturbances in calcium homeo stasis similar to that seen in patients with idiopathic hypercalciuria, 42 including marked hyper calciuria, increased dietary calcium absorption, elevated vitamin D levels and disturbances in bone (reduced trabecular and cortical mass), which suggests a key regulatory role for TRPV5. The human gene coding for TRPV5 is located on chromosome 7q35. 43 Molecular screening of TRPV5 in 20 patients with renal hypercalciuria revealed eight single nucleotide base changes although functional character ization of these variants failed to show differences from wildtype TRPV5. 44 
Macromolecules and inhibitors
Several macromolecules, including TammHorsfall urinary glycoprotein (also known as uromodulin), osteopontin, bikunin (α1microglobulin) and nephro calcin, have been detected in calcium oxalate kidney stones formed by humans. 45, 46 Attempts to assign a patho genic role for these macromolecules, by measuring their urinary excretion patterns in stone formers versus con trols, and assessing their in vitro effect on calcium oxalate crystal formation or adhesion to renal tubular epithelial cells, have yielded contradictory results. 47, 48 The role of single nucleotide polymorphisms in the genes coding for these molecules and the risk of idiopathic calcium oxalate stone formation has been examined. A strong association of several single nucleotide polymorphisms in the osteopontin gene (T593A, C6982T, rs1126616 and -156delG) with urinary stone formation has been demon strated in Turkish, Japanese and Taiwanese popula tions. [49] [50] [51] Similarly, a poly morphism (I550V) in the gene coding for the solute carrier family 13 member 2, a major regulator of urinary citrate excre tion, has been shown to be associated with the risk of recurrent calciumcontaining stones. 52 Urinary citrate is a potent inhibitor of calcium oxalate crystal formation in human urine. Patients homozygous for this variant showed a significantly lower urinary citrate level than did patients heterozygous for this variant. 52 
Genome-wide association studies
The familybased linkage and candidate gene approach to identifying genetic variants that confer heritability is Notably, these risk variants also seemed to associate with biochemical parameters pertinent to calcium metab olism, including urinary calcium, serum bicarbonate and parathyroid hormone level. CLDN14 is a member of the claudin gene family, which codes for membrane proteins that regulate paracellular ion transport, with expression in cochlear sensory epithelium. Until now, variants in CLDN14 had only been described in patients with nonsyndromic autosomal recessive deafness.
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Rare (monogenic) forms of urolithiasis
Recent insights into the genetic basis and patho physiology of monogenic causes of urolithiasis have underscored the role of enzymes as well as transporter, channel and recep tor proteins expressed in the renal tubule ( Figure 1 ) and in other nonrenal epithelia. Although these Mendelian traits account for only 2% and 10% of adult and pedi atric kidney stone formers, respectively, 54,55 they are characterized by more severe stoneforming phenotypes than the common polygenic form, and by progressive renal impairment. Dent disease, primary hyperoxaluria, adenine phospho ribosyltransferase (APRT) deficiency, hypoxanthineguanine phospho ribosyltransferase (HPRT) deficiency and familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC) in par ticular, are associated with renal failure. The forma tion of crystals within renal tubules in these conditions results in an injurious inflammatory response that leads to interstitial fibrosis and development of endstage renal disease. The major genetic defects, classified according to their specific stoneforming metabolic risk factor, are summarized in Tables 2 and 3 .
Urolithiasis associated with hypercalciuria Dent disease Inactivating mutations of CLCN5 are the cause of Dent disease, a collection of syndromes characterized by a proximal tubulopathy, low molecular weight protein uria, hypercalciuria, calcium urolithiasis, nephro calcinosis and progressive renal insufficiency, with or without bone disease. 56, 57 Endstage renal failure is often observed in affected males by midadulthood. 56 Before discovery of CLCN5 as the causative gene, several previ ously described syndromes were considered to be sepa rate diseases: Xlinked recessive nephrolithiasis with renal failure, Xlinked recessive hypophosphatemic rickets, low molecular weight proteinuria with hyper calciuria and nephrocalcinosis, and Japanese idiopathic low molecular weight proteinuria. Identification of the specific genetic defect has provided a unifying diag nosis. Locus heterogeneity has also been described, with detec tion of OCRL1 mutations in 13 male probands with a phenotype resembling Dent disease, but negative for CLCN5 mutations.
58 CLCN5 and OCRL1 code for dis tinctly different proteins with different expression pat terns and functions. CLCN5 codes for a voltagegated H + /Cl -exchanger expressed in the cortical proximal tubule, medullary thick ascending limb of Henle's loop and αintercalated cells, whereas OCRL1 codes for an inositol polyphosphate 5phosphatase, a key regulator of protein trafficking at the plasma membrane that has a far more ubiquitous expression than the H + /Cl -exchanger. 59 The mechanism by which mutations in these genes cause hypercalciuria and its attendant stoneforming manifestations in Dent disease remains unclear although disruption of endosomal membrane trafficking might be a common pathogenic feature. OCRL1 mutations are also the cause of Lowe syndrome, which is characterized by congenital cataracts, mental retardation and defective proximal renal tubular reabsorption, which is sometimes associated with hypercalciuria and nephrocalcinosis. 60 Therefore, it is not readily understood how these muta tions can also result in an isolated form of proximal renal tubular wasting as seen in patients with Dent disease. At present, CLCN5 mutations account for the major ity of families with Dent disease, 58, 61 with more than 80 pathogenic variants spread throughout the coding region described to date. Correlations between genotype and phenotype are lacking thus far. 62, 63 Molecular screening of CLCN5 in a limited subset of 32 patients with idio pathic hypercalciuria did not reveal any sequence vari ants in CLCN5, thus failing to show an association with this common condition. they function as chargeselective channels. 65 Lossof function mutations in CLDN16 give rise to the syndrome of FHHNC, a rare autosomal recessive tubular dis order characterized by magnesium and calcium wasting, poly uria, nephrolithiasis, nephrocalcinosis and progres sive renal failure, which is typically of early onset. 4, 5, 66 A similar syndrome that is characterized by ocular abnormali ties in addition to renal tubular manifestations is caused by mutations in CLDN19, and so far recognized in families of Swiss, Spanish and Turkish descent. 5 In the kidney, claudin16 and claudin19 share parallel expres sion in the thick ascending limb of Henle's loop and distal convoluted tubule, which is essential for paracellular reabsorption of calcium and magnesium. Interestingly, claudin16 and claudin19 form a complex in the thick ascending limb of Henle's loop, which is required for formation of the cationselective paracellular channel in tight junctions of this nephron segment.
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Over 25 mutations in CLDN16 have now been cata logued, including missense, nonsense, frameshift and splice site changes, with evidence that complete loss offunction variants give rise to earlier symptom onset and more rapid decline in renal function than other variants. 68 Interestingly, a CLDN16 missense variant (T233R) has also been reported in two of 11 families with isolated hypercalciuria. 69 Distal renal tubular acidoses A number of monogenic clinical conditions are associ ated with impaired distal renal tubular function, which result in reduced acidification capacity, alkaline urine, hypocitraturia and hypercalciuria. All of these factors predispose to the precipitation of calcium phosphate and/or oxalate in renal parenchyma or in renal tubules, and hence lead to urolithiasis and nephrocalcinosis. Functional alterations of the band 3 anion transport protein, as a result of SLC4A1 mutations, are the cause of an autosomal dominant form of urolithiasis seen in some families, 70, 71 whereas mutations in genes coding for hydrogen ATPases, ATP6V0A4 and ATP6V1B1, give rise to autosomal recessive transmission.
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Hypophosphatemic rickets with hypercalciuria In 1985, Tieder et al. first reported rickets, renal phos phate wasting, hypophosphatemia, upregulation of 1,25dihydroxyvitamin D expression and hyper calciuria in a large consanguineous Bedouin kindred. 76 The syn drome, inherited as an autosomal recessive trait, was coined hypophosphatemic rickets with hypercalciuria. Two groups subsequently identified lossoffunction mutations in SLC34A3, the gene coding for the sodium dependent phosphate transport protein 2C, to be the cause of this condition. 77, 78 Although not recognized as part of the phenotype of the original kindred, subsequent reports have confirmed nephrolithiasis in affected homo zygous individuals 77, 79, 80 and heterozygous carriers with variable phenotype. 81 Urolithiasis associated with other abnormalities
2,8-Dihydroxyadeninuria (APRT deficiency)
Deficiency of APRT, a key enzyme in human purine metabolism, causes accumulation of adenine. Oxidation of excess adenine by xanthine dehydrogenase gives rise to 2,8dihydroxyadenine, a highly insoluble compound in human urine. Formation of 2,8dihydroxyadenine crystals causes kidney stones and is injurious to renal parenchyma (Figure 2) . Patients often present with kidney stones, but might also present with renal failure in the absence of stones or nephrocalcinosis. Owing to the radiolucent appearance of 2,8dihydroxyadenine stones they can be confused with uric acid on radiographic studies. Two types (I and II) are recognized, based on genotype and degree of residual APRT activity. Both types are inherited as autosomal recessive traits. 82 The diag nosis is indicated by stones comprised of 2,8dihydroxy adenine on analysis by infrared spectroscopy or detection of 2,8dihydroxyadenine crystals in the urine, which have a characteristic appearance on microscopy ( Figure 3) , and can be confirmed by measurement of APRT activity in erythrocyte lysates and/or by molecular genetic testing. APRT deficiency has been well described in Icelandic and Japanese populations with detection of founder mutations (Asp65Val and Met136Thr, respectively). [83] [84] [85] A splice site mutation (IVS4+2insT) has also been reported in several European families 86, 87 and confirmed recently in a large cohort from France. 88 The prevalence of APRT defi ciency in the general population is unknown. However, estimates of heterozygosity of ~1%, based on Caucasian and Japanese allelic frequencies, and 1 in 250 based on measure ment of APRT activity in erythro cyte lysates from an Australian population, suggest that it may be more frequent than clinically recognized. 89, 90 Treatment with allopurinol inhibits the production of 2,8dihydroxy adenine and is effective in reducing stone formation as well as ameliorating renal damage. 88 
HPRT deficiency
The vital physiological role of HPRT activity in human purine metabolism is emphasized by its absence, which results in Lesch-Nyhan syndrome. This syndrome is characterized by hyperuricemia, hyperuricosuria, early onset uric acid urolithiasis (most commonly in the first year of life) and neurological complications (such as mental retardation and selfmutilation). 91 In cases of partial HPRT enzyme deficiency, referred to as KelleySeegmiller syndrome, less severe phenotypic manifesta tions are observed (for example, hyperuricemia and gout), correlated in part to residual HPRT enzymatic activity. 92 Both syndromes result from 'private' or de novo mutations in the Xlinked HPRT1 gene, with >300 muta tions described so far. [93] [94] [95] The diagnosis is confirmed by determination of HPRT activity in erythrocyte lysates, skin fibroblasts or by molecular genetic analysis. 96 Prenatal testing is available using amniocytes or cho rionic villus cells for HPRT enzymatic assay or genetic testing. 97, 98 Of note is the potential for renal failure, which can be of pediatric onset. 99 Treatment with allopurinol is effective in reducing the hyperuricemia and hyper uricosuria, but in the case of complete HPRT deficiency (that is, Lesch-Nyhan syndrome), xanthine urolithiasis can develop during allopurinol treatment as a result of urinary elevations of xanthine and hypoxanthine levels, and requires adjustments in dosing. 96 Xanthinuria/hypoxanthinuria Deficiency of xanthine dehydrogenase as a result of mutations in XDH also results in impaired purine degrada tion. In this case, the condition is character ized by increased urinary levels of xanthine and hypo xanthine, but with hypouricemia and hypouricosuria.
The disease is most common in Mediterranean and Middle Eastern regions of the world and is inherited as an autosomal recessive trait. 100 The development of xanthine stones in affected patients is variable. 
Hyperoxaluria
The primary hyperoxalurias are rare inborn errors of glyoxylate metabolism that result in marked hepatic overproduction and urinary excretion of oxalate, typi cally in excess of 1.0 mmol/1.73 m 2 per 24 h (normal <0.46 mmol/1.73 m 2 per 24 h). The prevalence of the most frequently encountered form of the disease, type 1 primary hyperoxaluria, estimated from a French epidemiological survey, is 1-3 per million population. 101 Prevalence in the USA is unknown. The very high urine oxalate concentra tions favor calcium oxalate crystallization and aggrega tion, which gives rise to calcium oxalate kidney stone formation and nephrocalcinosis. Most patients develop symptoms as a result of stone disease, although a minor ity initially present with endstage kidney failure. Signs and symptoms most commonly develop in early child hood, although the age at presentation varies widely, from infancy to adulthood. An inflamma tory response, medi ated by the presence of calcium oxalate crystals in renal tubules and interstitium, causes progressive renal damage over time (Figure 4) . In patients of the International Primary Hyperoxaluria Registry, endstage kidney failure occurred at a median age of 33 years, but can be seen in patients with primary hyperoxaluria type 1 as early as infancy or as late as the sixth decade of life. 102 Among the three types of primary hyperoxaluria, type 1 accounts for the majority of patients and is the most clinically severe. An evidencebased, systematic approach can guide the diagnosis of the primary hyperoxalurias. 103 Primary hyperoxaluria type 1 is caused by a defi ciency of the liverspecific, peroxisomal enzyme alanine-glyoxylate aminotransferase (AGT), which requires vitamin B 6 (pyridoxal phosphate) as a co factor. 104 AGT catalyzes the conversion of glyoxylate to glycine, but in its absence, glyoxylate is oxidized to oxalate and reduced to glycolate instead. Persistent and marked hyperoxaluria is evident from infancy onwards in patients with primary hyperoxaluria type 1, although the degree of hyperglycolic aciduria is variable. Over 100 mutations in the gene coding for AGT have now been described. Molecular diagnosis is possible in most patients [105] [106] [107] [108] and availability of genotyping has also facilitated specific treatment. Approximately onethird of patients experience a substantial reduction in urine oxalate excretion while receiving pharmacological doses of vitamin B 6 , a response that has been associated with the most common mutation (c.508G>A, G170R), which causes a unique peroxisometomitochondria trafficking defect, 109 and also with a few other mutations. 110 High fluid intake and inhibitors of calcium oxalate crystalliza tion (citrate or neutral phosphate) are used to ameliorate stone formation and renal injury. 111 At present, ortho topic liver transplantation remains the sole definitive means of correcting the metabolic defect. Simultaneous kidney transplantation is typically performed to manage renal failure.
Deficiency of cytosolic hepatic glyoxylate reductase/ hydroxypyruvate reductase (GRHPR) activity causes primary hyperoxaluria type 2.
112 GRHPR has dual enzy matic activities, catalyzing the reductions of glyoxyl ate to glycolate and of hydroxypyruvate to dglycerate in human liver. Although signs and symptoms and elevations in urinary oxalate may parallel those seen in primary hyperoxaluria type 1, 113 there are a few notable differences between the two disorders. In primary hyper oxaluria type 2, lglyceric aciduria is often present with the hyperoxaluria. 114 Pyridoxine (vitamin B 6 ) treatment is not effective in primary hyperoxaluria type 2. In contrast to AGT, whose activity is liverspecific, tissue expression of GRHPR is not limited to liver. Orthotopic liver trans plantation is not currently recommended for treatment of primary hyperoxaluria type 2. Rather, kidney only transplantation is used to address renal failure. To date, fewer than 20 GRHPR mutations have been described, with a minor deletion (c.103delG) accounting for the majority of primary hyperoxaluria type 2 alleles (allelic frequency of ~37% in Caucasian samples). 105, 115, 116 A third type of primary hyperoxaluria, primary hyper oxaluria type 3, has been recognized clinically for some time in patients who have early onset of nephrolithiasis and marked hyperoxaluria that is indistinguishable from that seen in the other two types of primary hyperoxaluria, but have normal hepatic AGT and GRHPR activities. 117 Mutations in the HOGA1 gene have been determined to be responsible. 118, 119 The disease seems to be auto somal recessive, although its inheritance is not yet fully understood. 119 The hyperoxaluria is believed to result from deficiency of the hepatic mitochondrial enzyme 4hydroxy2oxoglutarate aldolase. Early experience indicates that the prevalence of primary hyperoxaluria type 3 is similar to that of primary hyperoxaluria type 2. 
Cystinuria
Cystinuria is an autosomal recessive trait caused by defective proximal renal and gastrointestinal reabsorp tion of cystine and the dibasic amino acids as a result of mutations in the genes SLC3A1 and SLC7A9, which code for these amino acid transporters. [120] [121] [122] [123] The reported prevalence of cystinuria varies widely depending on the population tested, ranging from 1 in 2,500 in Libyan Jews to 1 in 100,000 in Sweden. 124, 125 Identification of the causative loci has facilitated a molecularbased classifica tion system (dividing cystinuria into types A and B), which replaces the prior characterization scheme that relied largely on urinary amino acid excretion pat terns (and divided cystinuria into types I and nonI) in obligate heterozygotes. 126 Type A disease is the result of two mutations in SLC3A1 and type B disease results from two mutations in SLC7A9, although mutations of these genes do not explain all cases of either type. 127 To date, more than 200 pathogenic single nucleotide vari ants (coding and noncoding) and large gene rearrange ments have been described. 127 The markedly elevated levels of urinary cystine, a highly insoluble compound (solubility ~300 mg/l), predispose to recurrent stone formation. Hexagonal cystine crystals in the urine are patho gnomonic for cystinuria ( Figure 5 ). Frequent stones are the most common manifestation, although some patients also experience a gradual loss in renal function. The mainstay of treatment consists of urinary dilution, urinary alkalinization and reduction of cystine to its more soluble metabolite cysteine with the use of tiopronin and dpenicillamine.
Diagnosis of monogenic causes of urolithiasis
Clinical recognition of the hereditary forms of uro lithiasis can be challenging owing to their rarity and wide spectrum of disease expression over the course of a lifetime as well as the fact that the different disorders have common signs and symptoms, including overlap with idiopathic calcium oxalate urolithiasis. Delays in diagnosis are common, with identification of some patients only after the onset of renal failure or when there is disease recurrence in the transplanted kidney after transplantation. In a US survey of 102 patients with primary hyperoxaluria, a delay in diagnosis of several years was reported in 42% patients, including 30% in whom the diagnosis was not established until after the onset of endstage renal disease. 128 Delay in diagnosis until after endstage renal disease was also observed in 20% of patients from the International Primary Hyperoxaluria Registry. 102 Similar under recognition of the potential for irreversible loss of renal function, even in the absence of urolithiasis, was published in an article on three adult patients with 2,8dihydroxy adeninuria. 129 The diagnosis of monogenic forms of urolithiasis should therefore be considered in any patient with childhoodonset kidney stones, frequent recurrences of urolithiasis in adolescence or adulthood, nephrocalcinosis or otherwise unexplained renal failure at any age and in those with a family history of these disease manifestations.
Identification of the causative genes and knowledge of their pathogenic sequence variants in monogenic forms of urolithiasis have contributed greatly to their earlier diagnosis and treatment. The feasibility of molecular genetic testing using DNA extracted from peripheral white blood cells has replaced the necessity for more invasive diag nostic testing in many instances, including measurement of enzymatic activity in liver tissue or in skin fibroblasts, and blood samples can be transported easily to specialized referral diagnostic laboratories. Moreover, genetic testing has made family screen ing and prenatal testing possible. Genotyping has also become a guide to treatment by predicting a response to therapy in some cases. The accuracy provided by genetic testing combined with registries for patients with these rare diseases are transforming knowledge about disease behavior, and providing new opportunities for the study of effective treatments.
Patient registries for rare disorders
Owing to the rarity and phenotypic heterogeneity of the monogenic forms of nephrolithiasis, most physicians will have limited familiarity with disease expression, appropriate diagnostic steps and treatment. Progress in understanding the natural history of these disorders has been slow as a result of the small numbers of patients who are widely scattered geographically. The recent crea tion of patient registries of rare diseases holds promise to overcome these challenges by facilitating recruitment of sufficient numbers of affected patients for study and participation in clinical trials. Early experience of the Rare Kidney Stone Consortium, which houses patient registries for primary hyperoxaluria, Dent disease, APRT deficiency and cystinuria, confirms the feasibility of this approach.
Conclusions
Our knowledge of the influence of genes in polygenic and monogenic forms of urolithiasis has evolved greatly in the past century, eliciting an appreciation for the participatory role of a variety of proteins, including enzymes, transporters, channels and receptor proteins in the kidney and other organ systems. Family linkage and candidate gene studies have highlighted aberra tions of calcium metabolism in the common poly genic form of urolithiasis. In the future, highpowered genomewide association and replication studies will undoubtedly identify additional risk loci, opening an avenue for identification of new therapeutic targets and approaches to treatment. Advances in molecular genetics and pharmaco genomics have revolutionized diagnosis and treatment for rare monogenic disorders, while at the same time providing important insights into mechanisms that might contribute to the more common polygenic forms of urolithiasis. Development of patient registries for rare diseases will serve to improve patient outcomes, by raising awareness through advocacy, research and consolidation of clinical experience.
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